


## SKLB-197

<b>Cat. No.:</b>	HY-144217		
<b>CAS No.:</b>	2713577-16-1		
<b>Molecular Formula:</b>	C <sub>25</sub> H <sub>24</sub> N <sub>6</sub> O		
<b>Molecular Weight:</b>	424.5		
<b>Target:</b>	ATM/ATR		
<b>Pathway:</b>	Cell Cycle/DNA Damage; PI3K/Akt/mTOR		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



## SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 100 mg/mL (235.57 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	<b>Preparing Stock Solutions</b>	1 mM	2.3557 mL	11.7786 mL	23.5571 mL
		5 mM	0.4711 mL	2.3557 mL	4.7114 mL
10 mM		0.2356 mL	1.1779 mL	2.3557 mL	
Please refer to the solubility information to select the appropriate solvent.					
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (5.89 mM); Clear solution				

## BIOLOGICAL ACTIVITY

<b>Description</b>	SKLB-197 showed an IC <sub>50</sub> value of 0.013 μM against ATR but very weak or no activity against other 402 protein kinases. It displayed potent antitumor activity against ATM-deficient tumors both in vitro and in vivo.
<b>IC<sub>50</sub> &amp; Target</b>	ATR 0.013 μM (IC <sub>50</sub> )

## REFERENCES

[1]. Bin H, et al. Discovery of a potent and highly selective inhibitor of ataxia telangiectasia mutated and Rad3-Related (ATR) kinase: Structural activity relationship and antitumor activity both in vitro and in vivo. *Eur J Med Chem.* 2022 Feb 12;232:114187

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA